Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manon Roche

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Molecules (Basel, Switzerland)|January 29, 2013
Original TDAE strategy using propargylic chloride: rapid access to 1,4-diarylbut-3-ynol derivativesManon Roche, Thierry Terme, Patrice Vanelle
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|July 24, 2019
Efficacy and safety of plasma exchange using a double viral inactivated and prion reduced solvent/detergent fresh frozen plasma for the treatment of thrombotic microangiopathy: The first French experience in a single centerPascale Poullin, Nicolas Delmotte, Frederick Sanderson, et al.
Pharmaceuticals (Basel, Switzerland)|September 28, 2024
From the "One-Molecule, One-Target, One-Disease" Concept towards Looking for Multi-Target Therapeutics for Treating Non-Polio Enterovirus (NPEV) InfectionsHugo Roux, Franck Touret, Pascal Rathelot, et al.
International Journal of Antimicrobial Agents|May 29, 2016
Misuse of antibiotics reserved for hospital settings in outpatients: a prospective clinical audit in a university hospital in Southern FranceManon Roche, Charléric Bornet, Philippe Monges, et al.
Drugs - Real World Outcomes|June 25, 2021
Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Real Life: One-Year Clinical and Economic OutcomesRomain Giraud, Nicolas Delmotte, Sophie Gensollen, et al.
Journal of Chemotherapy (Florence, Italy)|June 28, 2017
News on therapeutic management of MDR-tuberculosis: a literature reviewLucie Barthod, Jean-Guillaume Lopez, Christophe Curti, et al.
ACS Infectious Diseases|December 23, 2024
Non-Polio Enterovirus Inhibitors: Scaffolds, Targets, and Potency─What's New?Hugo Fernando Georges Roux, Franck Touret, Pascal Rathelot, et al.
European Journal of Medicinal Chemistry|March 8, 2014
Synthesis, biological activity and structure-activity relationship of 4,5-dimethoxybenzene derivatives inhibitor of rhinovirus 14 infectionManon Roche, Céline Lacroix, Omar Khoumeri, et al.
Annals of Intensive Care|August 11, 2025
Assessing the carbon footprint of the initial 24 h post-severe trauma admission in a French ICU: a pilot studyCandice Marion, Matthieu Bernat, Emmanuelle Hammad, et al.
European Journal of Medicinal Chemistry|April 7, 2016
VP1 crystal structure-guided exploration and optimization of 4,5-dimethoxybenzene-based inhibitors of rhinovirus 14 infectionLaurène Da Costa, Manon Roche, Els Scheers, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Molecules (Basel, Switzerland)|January 29, 2013
Original TDAE strategy using propargylic chloride: rapid access to 1,4-diarylbut-3-ynol derivativesManon Roche, Thierry Terme, Patrice Vanelle
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|July 24, 2019
Efficacy and safety of plasma exchange using a double viral inactivated and prion reduced solvent/detergent fresh frozen plasma for the treatment of thrombotic microangiopathy: The first French experience in a single centerPascale Poullin, Nicolas Delmotte, Frederick Sanderson, et al.
Pharmaceuticals (Basel, Switzerland)|September 28, 2024
From the "One-Molecule, One-Target, One-Disease" Concept towards Looking for Multi-Target Therapeutics for Treating Non-Polio Enterovirus (NPEV) InfectionsHugo Roux, Franck Touret, Pascal Rathelot, et al.
International Journal of Antimicrobial Agents|May 29, 2016
Misuse of antibiotics reserved for hospital settings in outpatients: a prospective clinical audit in a university hospital in Southern FranceManon Roche, Charléric Bornet, Philippe Monges, et al.
Drugs - Real World Outcomes|June 25, 2021
Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Real Life: One-Year Clinical and Economic OutcomesRomain Giraud, Nicolas Delmotte, Sophie Gensollen, et al.
Journal of Chemotherapy (Florence, Italy)|June 28, 2017
News on therapeutic management of MDR-tuberculosis: a literature reviewLucie Barthod, Jean-Guillaume Lopez, Christophe Curti, et al.
ACS Infectious Diseases|December 23, 2024
Non-Polio Enterovirus Inhibitors: Scaffolds, Targets, and Potency─What's New?Hugo Fernando Georges Roux, Franck Touret, Pascal Rathelot, et al.
European Journal of Medicinal Chemistry|March 8, 2014
Synthesis, biological activity and structure-activity relationship of 4,5-dimethoxybenzene derivatives inhibitor of rhinovirus 14 infectionManon Roche, Céline Lacroix, Omar Khoumeri, et al.
Annals of Intensive Care|August 11, 2025
Assessing the carbon footprint of the initial 24 h post-severe trauma admission in a French ICU: a pilot studyCandice Marion, Matthieu Bernat, Emmanuelle Hammad, et al.
European Journal of Medicinal Chemistry|April 7, 2016
VP1 crystal structure-guided exploration and optimization of 4,5-dimethoxybenzene-based inhibitors of rhinovirus 14 infectionLaurène Da Costa, Manon Roche, Els Scheers, et al.
Pageof 2